Scarica l'app Stockscreener
1.195
1.27%
0.015
Dopo l'orario di chiusura:
1.18
-0.015
-1.26%
60 Degrees Pharmaceuticals Inc Borsa (SXTP) Ultime notizie
60 Degrees Pharmaceuticals (NASDAQ: SXTP) files to register 1.77M resale shares from warrant deal - Stock Titan
60 Degrees Q2 revenue jumps 106% to $208K; loss widens - scanx.trade
ARAKODA maker reports about $2.4M Q2 loss with about $208K revenue - Stock Titan
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results - Yahoo Finance
60 Degrees Pharmaceuticals (SXTP) flags going concern risk as losses deepen - Stock Titan
60 Degrees Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:SXTPW - TradingView
60 Degrees Pharmaceuticals Shareholders Approve Key Governance Actions - The Globe and Mail
60 Degrees Pharmaceuticals Inc (SXTP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reports 2026 shareholder vote outcomes - Stock Titan
Lind Global Fund III (SXTP) discloses 5.45% stake with warrant conversion cap - Stock Titan
60 Degrees Pharmaceuticals Completes Private Placement to Raise Capital - TipRanks
60 Degrees Pharmaceuticals Raises $1.0 Million in Private Placement of Stock and Warrants - TradingView
60 Degrees Pharmaceuticals (NASDAQ: SXTP) raises $1M in warrant-backed private placement - Stock Titan
60 Degrees Pharmaceuticals issues Series A, Series B warrants exercisable at $1.49 in $1 million private placement - Bitget
60 Degrees Pharmaceuticals (SXTP) Slips 6.4% as Shares Test Key Support at $1.11Bear Pennant - dars.gov.et
60 Degrees Pharmaceuticals raises $1M in private placement By Investing.com - Investing.com Canada
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
60 Degrees Pharmaceuticals, Inc. announced that it has received $0.999618 million in funding - marketscreener.com
60 Degrees Pharmaceuticals Announces Minimum Enrollment - GlobeNewswire
60 Degrees Pharmaceuticals hits babesiosis trial enrollment milestone - scanx.trade
60 Degrees Pharmaceuticals Inc (SXTP) Balance Sheet - TradingKey
60 Degrees Pharmaceuticals Inc - TradingKey
60 Degrees Pharmaceuticals Inc (SXTP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
60 Degrees Pharmaceuticals Inc (SXTP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SXTP|60 Degrees Pharmaceuticals Inc|Price:1.140| - TradingKey
60 Degrees Pharmaceuticals Secures US Patent for Tafenoquine Lung Infection Treatment - scanx.trade
60 Degrees Pharmaceuticals Inc (SXTP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
60 Degrees Pharmaceuticals (SXTP) Slips 0.67% as Stock Hovers Near SupportCommon Gap - dars.gov.et
Enterprise value to revenue forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTP - TradingView
60 Degrees Pharmaceuticals Inc (SXTP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
60 Degrees Pharmaceuticals (SCTP) Proxy filing Summary - Quartr
60 Degrees Pharmaceuticals (SCTP) Registration Filing Summary - Quartr
60 Degrees Pharmaceuticals (SXTP) Edges Lower Near Support as Volume Remains SubduedWyckoff Accumulation - dars.gov.et
60 Degrees Pharmaceuticals: FDA-Approved Malaria & Babesiosis Treatments, Clinical Pipeline, and Commercial Growth (2026 Investor Update) – Minichart - Minichart
60 Degrees updates strategy for ARAKODA and profitability - TipRanks
60 Degrees Pharmaceuticals updates investor presentation; outlines Arakoda babesiosis trials, targets profitability - TradingView
Frontier tech research, news & data - MLQ.ai
60 Degrees Pharmaceuticals Inc. (SXTP) Q1 2026 Earnings: EPS Misses Estimates by Wide MarginGuidance Revision Trend - dars.gov.et
SXTP Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerEarnings Season Preview - po-news-eg.net
Enterprise value to EBITDA forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTP - TradingView
60 Degrees Pharmaceuticals, Inc. Warranton 60 Degrees Ph Financial Disclosures & SEC Filings - TradingView
Price to book forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTP - TradingView
60 Degrees Pharmaceuticals (NASDAQ: SXTP) Files 8-K Report Detailing Company Updates and Security Information - Minichart
Price to earnings forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTP - TradingView
Interim Trial Plan Finalized for Tafenoquine Babesiosis Study - TipRanks
60 Degrees Pharmaceuticals readies interim analysis plan for tafenoquine babesiosis trial - TradingView
60 Degrees Pharmaceuticals (SXTP) sets tafenoquine babesiosis interim analysis and sNDA path - Stock Titan
Price to earnings forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTPW - TradingView
60 Degrees Pharmaceuticals to Advance Castanospermine for Tick-Borne Diseases Through Florida State University Deal - Moomoo
60 Degrees Pharma gets option to pursue tick-borne disease drug - Stock Titan
60 Degrees Pharma secures option for tick-borne disease IP - scanx.trade
Price to sales forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTP - TradingView
Enterprise value to EBIT forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTP - TradingView
SXTP | 60 Degrees Pharmaceuticals, Inc. Executive Compensation - Quiver Quantitative
SXTPW | 60 Degrees Pharmaceuticals, Inc. Executive Compensation - Quiver Quantitative
Equity plan hike and reverse split up for 60 Degrees (SXTP) shareholder vote - Stock Titan
60 Degrees Pharma babesiosis study clears safety review - Investing.com UK
60 Degrees Pharma babesiosis study clears safety review By Investing.com - Investing.com Nigeria
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue - Yahoo Finance Singapore
60 Degrees Pharma's B-Free babesiosis trial advances after DSMB review - scanx.trade
SXTP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
SXTP Forecast — Price Target — Prediction for 2027 - TradingView
60 Degrees Pharmaceuticals, Inc. Actuals & Estimates (BOATS:SXTP) - TradingView
60 Degrees Pharmaceuticals Inc (SXTP) Valuation: PE, PB & Fair Value Analysis - TradingKey
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):